Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the future treatment of solid and hematologic cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that its oral non-covalent BTK-inhibitor, SNS-062, treats ibrutinib-resistant chronic lymphocytic leukemia. Sunesis is also supporting investigator-led studies of vosaroxin in acute myeloid leukemia.

We have built a highly experienced cancer drug development organization committed to advancing our oncology pipeline through:

Delivering on our Promise

Develop and commercialize medicines with significant potential to improve cancer care

Leadership

Experience and passion to build a company focused on improving the lives of people with cancer

Commitment

We are in this business because we believe we can make a difference. Read about our commitment to improving the lives of people with cancer and their loved ones.